Adult Psoriasis
Treatment advancements merit updates to dermatological disqualifiers in the military
Due to medical advancements, researchers are calling for an update to the U.S. Department of Defense’s policies restricting individuals with psoriasis and atopic dermatitis from joining and remaining in the military, according to a study.
First patient dosed in phase 2a trial of AX-158 for psoriasis
The first patient has been dosed in Artax Biopharma’s phase 2a trial evaluating the safety and biomarker responses of AX-158 in a first proof-of-mechanism trial in psoriasis, the company announced in a press release.
FDA postpones review of bimekizumab biologics license application
The FDA review of the biologics license application for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis has been postponed to the third quarter of 2023, UCB announced in a press release.
Bimekizumab sustains positive results in new, long-term data for psoriatic arthritis
UCB announced new long-term data from BE COMPLETE’s 52-week open label extension evaluating the efficacy and safety of bimekizumab in adults with active psoriatic arthritis, according to a press release.
FDA approves ‘high-concentration, citrate-free’ Yuflyma as ninth Humira biosimilar
The FDA has approved Celltrion USA’s Yuflyma as the ninth biosimilar to adalimumab for all eligible indications of the reference product, and the latest in a flood of biosimilars cleared for 2023 release in the United States.
European Medicines Agency recommends bimekizumab in two new indications
The European Medicines Agency has recommended granting marketing authorization for bimekizumab for the treatment of adults with axial spondyloarthritis and active psoriatic arthritis, according to a UCB press release.
Topical therapies fall short of patient expectations during psoriasis treatment
Once-daily halobetasol propionate 0.01% and tazarotene 0.045% fixed-combination lotion stands out as a favorable treatment option amid topical therapies deemed unsatisfactory by psoriasis patients, according to a systematic review.
Guselkumab improves PsA symptoms in 6-month real-world study
WAILEA, Hawaii — Patients with psoriatic arthritis treated with guselkumab for 6 months experienced a significant improvement in joint disease, skin disease and pain, according to a poster presented at the Maui Derm meeting.
VIDEO: Lowering cardiovascular risk factors necessary in psoriatic disease treatment
WAILEA, Hawaii — Bolstered by Mendelian randomization studies linking coronary artery disease and psoriasis, researchers are exploring how to combat cardiovascular events in patients with psoriatic disease, according to a presenter here.